Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

2.
3.

Systemic therapy for recurrent endometrial cancer: a review of North American trials.

Dellinger TH, Monk BJ.

Expert Rev Anticancer Ther. 2009 Jul;9(7):905-16. doi: 10.1586/era.09.54. Review.

PMID:
19589030
4.

Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience.

Kim HS, Kim JW, Wu HG, Chung HH, Park NH, Song YS, Kang SB, Lee HP.

J Obstet Gynaecol Res. 2010 Jun;36(3):598-604. doi: 10.1111/j.1447-0756.2010.01223.x.

PMID:
20598043
5.

Management of advanced-stage and recurrent endometrial cancer.

Ray M, Fleming G.

Semin Oncol. 2009 Apr;36(2):145-54. doi: 10.1053/j.seminoncol.2008.12.006. Review.

PMID:
19332249
6.

The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.

McMeekin DS, Filiaci VL, Thigpen JT, Gallion HH, Fleming GF, Rodgers WH; Gynecologic Oncology Group study.

Gynecol Oncol. 2007 Jul;106(1):16-22.

PMID:
17574073
7.

The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix.

Thigpen T, Vance RB, Khansur T.

Semin Oncol. 1995 Oct;22(5 Suppl 12):67-75. Review.

PMID:
7481864
8.

[Recent outline of chemotherapy for uterine endometrial cancer].

Watanabe Y, Hoshiai H.

Nihon Rinsho. 2004 Oct;62 Suppl 10:346-50. Review. Japanese. No abstract available.

PMID:
15535265
9.

Current treatment of metastatic endometrial cancer.

Temkin SM, Fleming G.

Cancer Control. 2009 Jan;16(1):38-45. Review.

10.

Adjuvant chemotherapy in endometrial carcinoma: overview of randomised trials.

Hogberg T.

Clin Oncol (R Coll Radiol). 2008 Aug;20(6):463-9. doi: 10.1016/j.clon.2008.04.001. Epub 2008 May 7. Review.

PMID:
18467080
11.
12.

New aspects of adjuvant therapy in endometrial cancer: current standards and future directions.

Sehouli J, Koensgen D, Oskay-Ozcelik G, Mustea A.

Crit Rev Oncol Hematol. 2008 Sep;67(3):204-12. doi: 10.1016/j.critrevonc.2008.02.011. Epub 2008 Apr 14. Review.

PMID:
18407513
13.

[A pilot study of combined chemotherapy with paclitaxel, doxorubicin and cisplatin for endometrial cancer].

Honma H, Sagae S, Terasawa K, Tanaka R, Chida M, Mizumoto H, Ishioka S, Saito T, Kudo R.

Gan To Kagaku Ryoho. 2004 Apr;31(4):549-53. Japanese.

PMID:
15114698
14.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

15.

[Chemotherapy of metastatic endometrial carcinoma. Review of the literature].

Pierga JY, Dieras V, Paraiso D, Pouillart P.

Bull Cancer. 1995 Dec;82(12):1005-18. Review. French.

PMID:
8745666
16.

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.

Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, Kline R, Burger RA, Goodman A, Burks RT.

J Clin Oncol. 2004 Jun 1;22(11):2159-66.

PMID:
15169803
17.

Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg CN, Bajorin DF, Bellmunt J.

J Clin Oncol. 2011 Jun 10;29(17):2432-8. doi: 10.1200/JCO.2011.34.8433. Epub 2011 May 9. Review.

PMID:
21555688
18.
19.

[The validity of chemotherapy in the treatment of endometrial cancer].

Fehr MK, Streich MS.

Gynakol Geburtshilfliche Rundsch. 2006;46(1-2):34-8. Review. German.

PMID:
16452818

Supplemental Content

Support Center